Oculis Holding AG (OCS) Stock

Oculis Holding AG (OCS) is a Healthcare stock trading at $11.20 (as of 2026-06-18), with a market capitalization of $764.51M and a trailing P/E of -6.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Oculis Holding AG is a clinical-stage biopharmaceutical company developing topical treatments for ophthalmic diseases affecting the front and back of the eye. Its pipeline includes OCS-01 for diabetic macular edema in Phase 3, OCS-02 for dry eye disease in Phase 2b, and OCS-05 in development for neuro-ophthalmic conditions.

Valuation — source: SEC EDGAR (first-party)
Price$11.20
Market Cap$764.51M
P/E Ratio-6.7
Price / Book3.90
Profitability & Growth — source: SEC EDGAR
Return on Equity-50.5%
Current Ratio5.96
Valuation vs Sector & Industry
Stock P/E-6.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-132.1%
vs Industry-139.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderEQT Fund Management S.a r.l. ($156.89M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORiad Sherif
Employees49
CountryCH
IPO Date2021-05-18

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by revenue (market cap unavailable); US-domiciled)

  • Alnylam Pharmaceuticals, Inc. (ALNY)
  • Viatris Inc. (VTRS)
  • Elanco Animal Health Incorporated (ELAN)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Bausch Health Companies Inc. (BHC)
  • Perrigo Company plc (PRGO)
  • Organon & Co. (OGN)
  • Universe Pharmaceuticals Inc. (UPC)
OCS earnings history · OCS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.